Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation

  title={Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation},
  author={Giulio Vistoli and Danilo De Maddis and Ana {\vC}ipak and Neven Žarkovi{\'c} and Marina Carini and Giancarlo Aldini},
  journal={Free Radical Research},
  pages={27 - 3}
Abstract Advanced lipoxidation end products (ALEs) and advanced glycation end products (AGEs) have a pathogenetic role in the development and progression of different oxidative-based diseases including diabetes, atherosclerosis, and neurological disorders. AGEs and ALEs represent a quite complex class of compounds that are formed by different mechanisms, by heterogeneous precursors and that can be formed either exogenously or endogenously. There is a wide interest in AGEs and ALEs involving… 
Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs
This review focuses on the receptors of AGEs, especially on the structural aspects of receptor–ligand interaction, and the diseases in which A GEs are involved, and aims to present AGE classification in subgroups.
Advanced Glycation End Products in the Skin: Molecular Mechanisms, Methods of Measurement, and Inhibitory Pathways
This work can help researchers acquire a deeper understanding of the relationship between AGEs and the skin and provides a basis for the development of effective ingredients that inhibit glycation.
The Modern Western Diet Rich in Advanced Glycation End-Products (AGEs): An Overview of Its Impact on Obesity and Early Progression of Renal Pathology
This review focuses on the AGE-induced kidney damage, by describing the molecular players involved and investigating its link to the excess of body weight and visceral fat, hallmarks of obesity.
Advanced Glycation End Products (AGEs), Glutathione and Breast Cancer: Factors, Mechanism and Therapeutic Interventions.
This review provides a strong platform to comprehend the etiology, mechanism and production of AGEs and glutathione along with the agents which can block their production, paving a way for the therapeutic intervention and an amicable solution to treat and manage breast cancer.
The Development of Maillard Reaction, and Advanced Glycation End Product (AGE)-Receptor for AGE (RAGE) Signaling Inhibitors as Novel Therapeutic Strategies for Patients with AGE-Related Diseases
The importance of “metabolic memory’, the “French paradox”, and the pharmacokinetics and therapeutic dosing of the effective natural compounds associated with pharmacogenetics in the treatment of AGE-related diseases are emphasized.
Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies
More prospective studies are needed to determine whether elevated serum AGEs and/or skin autofluorescence predict a decline in measures of mobility, and human intervention studies are required to investigate the beneficial effects of exogenous A GEs inhibitors on mobility outcomes.
Kidney, heart and brain: three organs targeted by ageing and glycation.
An overview of the current knowledge on the pathogenic role of AGEs is given by focusing on three AGE target organs: kidney, heart and brain, each of which is a major public health issue: chronic kidney disease, heart dysfunction and neurodegenerative diseases.


Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation.
It is hypothesized that AGEs cause perturbation in a diverse group of diseases, such as diabetes, inflammation, neurodegeneration, and aging, and it is proposed that targeting this pathway may represent a logical step in the prevention/treatment of the sequelae of these disorders.
An update on advanced glycation endproducts and atherosclerosis
The pathogenetic role of AGEs in the development, progression and instability of atherosclerosis, and the potential targets of this biological system for the prevention and treatment of cardiovascular disease are reviewed.
Dietary Advanced Glycation End Products and Aging
Results of several studies in animal models and humans show that the restriction of dietary AGEs has positive effects on wound healing, insulin resistance and cardiovascular diseases, and suggestions for future research are provided.
Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors
This review summarizes the signalling properties of ALEs and ALE‐precursors, their role in the pathogenesis of oxidative stress‐associated diseases, and the different agents efficient in neutralizing ALEs effects in vitro and in vivo.
Clinical review: The role of advanced glycation end products in progression and complications of diabetes.
  • S. Goh, M. Cooper
  • Biology
    The Journal of clinical endocrinology and metabolism
  • 2008
It is hoped that over the next few years, some of these promising therapies will be fully evaluated in the clinical context with the ultimate aim to reduce the major economical and medical burden of diabetes, its vascular complications.
The road to advanced glycation end products: a mechanistic perspective.
An overall detailed mechanistic analysis of protein glycation is presented for the first time and the pathways leading to several advanced glycation end products (AGEs) such as (carboxymethyl)lysine, pentosidine, and glucosepane are outlined, whereas other AGEs useful as potential biomarkers of glycation are only briefly mentioned.
Dietary advanced glycation endproducts (AGEs) and their health effects--PRO.
An exaggerated intake of thermally processed foods may exert in vivo diabetogenic and nephrotoxic effects, induce low-grade inflammation, enhance oxidative stress, and promote atherosclerosis.
Chemical Modification of Proteins by Lipids in Diabetes
  • J. Baynes
  • Medicine, Biology
    Clinical chemistry and laboratory medicine
  • 2003
The nature and source of AGEs/ALEs and the factors affecting their formation in tissue and plasma proteins are investigated, and the role of diabetes, dyslipidemia and renal disease in formation is reviewed.
Advanced glycation end-products: a review
The chemistry of advanced glycated end-product formation and their patho-biochemistry particularly in relation to the diabetic microvascular complications of retinopathy, neuropathy and nephropathy as well as their role in the accelerated vasculopathy observed in diabetes are discussed.